Improving the efficiency of infectious disease prevention trials using negative control outcome event times
利用负对照结局事件时间提高传染病预防试验效率AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要研究随机预防试验的治疗效应效率,利用负对照结局及有效影响函数进行调整,直接属于因果推断。
利用负对照结局事件时间提高传染病预防试验效率AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
Baseline covariate adjustment can enhance the efficiency of randomized trials by improving precision of treatment effect estimates. However, the precision gain depends on how strongly the baseline covariates are prognostic for the primary outcome. In randomized trials of infectious disease prevention interventions (e.g., vaccines or passively administered antibodies), an individual's exposure to the pathogen is a leading prognostic factor but is rarely measurable at baseline. Hence, conventional covariate adjustment offers limited precision gain in prevention trials. We propose adjusting for a negative control outcome (NCO) event time, which is causally unaffected by the intervention but shares overlapping exposure mechanisms with the primary outcome. We formalize assumptions under which adjustment for the NCO event time is valid, and show that right-censoring of the NCO event time further complicates adjustment. We derive the efficient influence function for the treatment-arm-specific survivor function of the primary outcome when both the primary outcome and the NCO event time are right-censored, and use it to construct a cross-fitted, one-step estimator that is multiply robust to nuisance misspecification and asymptotically efficient when the nuisances are estimated accurately. In numerical experiments, our estimator compares comparably to benchmarks when the NCO event time is uninformative, and gains precision as the NCO event time is more prognostic for the primary outcome. We apply our method to HVTN 704/HPTN 085, a randomized, double-blinded trial of VRC01, a broadly neutralizing antibody against HIV-1. Adjusting for the time to a bacterial sexually transmitted infection --- a negative control outcome for HIV-1 acquisition --- reduced the estimated variance of the prevention efficacy estimate by approximately 27%, compared to roughly 2.5% for baseline covariate adjustment.